Journal Article
. 1999 Aug; 17(1):93-100.
doi: 10.1200/JCO.1999.17.1.93.

Sequential dose-dense doxorubicin, paclitaxel, and cyclophosphamide for resectable high-risk breast cancer: feasibility and efficacy

C Hudis 1 A Seidman  J Baselga  G Raptis  D Lebwohl  T Gilewski  M Moynahan  N Sklarin  D Fennelly  J P Crown  A Surbone  M Uhlenhopp  E Riedel  T J Yao  L Norton  
Affiliations
  • PMID: 10458222
  •     14 citations

Abstract

Purpose: Dose-dense chemotherapy is predicted to be a superior treatment plan. Therefore, we studied dose-dense doxorubicin, paclitaxel, and cyclophosphamide (A-->T-->C) as adjuvant therapy.

Methods: Patients with resected breast cancer involving four or more ipsilateral axillary lymph nodes were treated with nine cycles of chemotherapy, using 14-day intertreatment intervals. Doses were as follows: doxorubicin 90 mg/m2 x 3, then paclitaxel 250 mg/m2/24 hours x 3, and then cyclophosphamide 3.0 g/m2 x 3; all doses were given with subcutaneous injections of 5 microg/kg granulocyte colony-stimulating factor on days 3 through 10. Amenorrheic patients with hormone receptor-positive tumors received tamoxifen 20 mg/day for 5 years. Patients treated with breast conservation, those with 10 or more positive nodes, and those with tumors larger than 5 cm received radiotherapy.

Results: Between March 1993 and June 1994, we enrolled 42 patients. The median age was 46 years (range, 29 to 63 years), the median number of positive lymph nodes was eight (range, four to 25), and the median tumor size was 3.0 cm (range, 0 to 11.0 cm). The median intertreatment interval was 14 days (range, 13 to 36 days), and the median delivered dose-intensity exceeded 92% of the planned dose-intensity for all three drugs. Hospital admission was required for 29 patients (69%), and 28 patients (67%) required blood product transfusion. No treatment-related deaths or cardiac toxicities occurred. Doxorubicin was dose-reduced in four patients (10%) and paclitaxel was reduced in eight (20%). At a median follow-up from surgery of 48 months (range, 3 to 57 months), nine patients (19%) had relapsed, the actuarial disease-free survival rate was 78% (95% confidence interval, 66% to 92%), and four patients (10%) had died of metastatic disease.

Conclusion: Dose-dense sequential adjuvant chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide (A-->T-->C) is feasible and promising. Several ongoing phase III trials are evaluating this approach.

Dose-intensive chemotherapy for locally advanced breast cancer.
J G Schrama, S Rodenhuis.
Curr Oncol Rep, 2000 Dec 21; 1(1). PMID: 11122794
Review.
New data on adjuvant therapy for breast cancer.
A C Wolff, N E Davidson.
Curr Oncol Rep, 2000 Dec 21; 1(1). PMID: 11122795
Review.
Sequential or alternating administration of docetaxel (Taxotere) combined with FEC in metastatic breast cancer: a randomised phase II trial.
M Spielmann, M Tubiana-Hulin, +5 authors, J C Eymard.
Br J Cancer, 2002 Mar 05; 86(5). PMID: 11875727    Free PMC article.
Premenopausal breast cancer: chemotherapy and endocrine therapy.
Herbert G Sayer, Roland Kath, Kay-Oliver Kliche, Klaus Höffken.
Drugs, 2002 Sep 25; 62(14). PMID: 12269848
Review.
Adjuvant chemotherapy for primary breast cancer.
Monica Fornier, Clifford Hudis.
Curr Oncol Rep, 2004 Dec 22; 7(1). PMID: 15610682
Review.
Dose-dense adjuvant chemotherapy for primary breast cancer.
Monica Fornier, Larry Norton.
Breast Cancer Res, 2005 Mar 04; 7(2). PMID: 15743513    Free PMC article.
Is Higher Efficacy Always at the Price of More Side Effects during Chemotherapy?
Brigitte Mlineritsch.
Breast Care (Basel), 2009 Jan 01; 4(3). PMID: 20847875    Free PMC article.
Dose-dense chemotherapy in nonmetastatic breast cancer: a systematic review and meta-analysis of randomized controlled trials.
Luisa Bonilla, Irit Ben-Aharon, +3 authors, Salomon M Stemmer.
J Natl Cancer Inst, 2010 Nov 26; 102(24). PMID: 21098761    Free PMC article.
Systematic Review.
Dose dense cyclophosphamide, methotrexate, fluorouracil is feasible at 14-day intervals: a pilot study of every-14-day dosing as adjuvant therapy for breast cancer.
Pamela Drullinsky, Steven M Sugarman, +15 authors, Clifford Hudis.
Clin Breast Cancer, 2010 Dec 15; 10(6). PMID: 21147686    Free PMC article.
A multicenter phase III prospective randomized trial of high-dose epirubicin in combination with cyclophosphamide (EC) versus docetaxel followed by EC in node-positive breast cancer. GOIM (Gruppo Oncologico Italia Meridionale) 9902 study.
P Vici, M Brandi, +11 authors, M Lopez.
Ann Oncol, 2011 Oct 04; 23(5). PMID: 21965475    Free PMC article.
Phase III randomized trial of dose intensive neoadjuvant chemotherapy with or without G-CSF in locally advanced breast cancer: long-term results.
Banu K Arun, Kapil Dhinghra, +16 authors, Gabriel N Hortobagyi.
Oncologist, 2011 Nov 02; 16(11). PMID: 22042783    Free PMC article.
Translating mathematical modeling of tumor growth patterns into novel therapeutic approaches for breast cancer.
Elizabeth Comen, Patrick G Morris, Larry Norton.
J Mammary Gland Biol Neoplasia, 2012 Sep 27; 17(3-4). PMID: 23011603
Review.
Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer.
Jeffrey A Jones, Elenir B C Avritscher, +3 authors, Linda S Elting.
Support Care Cancer, 2006 Apr 08; 14(6). PMID: 16601950
Review.
Alternating Magnetic Field-Triggered Switchable Nanofiber Mesh for Cancer Thermo-Chemotherapy.
Eri Niiyama, Koichiro Uto, +2 authors, Mitsuhiro Ebara.
Polymers (Basel), 2019 Apr 10; 10(9). PMID: 30960944    Free PMC article.